Live Breaking News & Updates on Nti covid 19 drug

Stay informed with the latest breaking news from Nti covid 19 drug on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Nti covid 19 drug and stay connected to the pulse of your community

Asthma drug found effective against COVID-19; here's how it works

The drug, used to reduce inflammation and make breathing easier for asthma patients, has been found effective against coronavirus.

Haryana , India , Indian-institute-of-science-iisc-bengaluru , Indian-institute , Covid-19-drug , Sthma-drug-found-effective-against-covid-19 , Ars-cov-2 , Ovid-19 , Ovid-19-pandemic , Rugs-effective-against-covid-19 , Nti-covid-19-drug

WHO launches safety monitoring study for molnupiravir in India, other countries

The primary objective of the study is to characterise and estimate the incidence of all adverse events, including serious adverse events, medication errors, off-label use and misuse occurring in enrolled patients.

United-states , India , United-kingdom , World-health-organization , Indian-council-of-medical-research , Central-drugs-standard-control-organisation , Indian-council , Medical-research , Olnupiravir , Ovid-19 , Nti-covid-19-drug

DRDO invites Express of Interest for bulk production of COVID drug 2-DG

New Delhi [India], June 9 (ANI): The Defence Research and Development Organisation (DRDO), which developed 2 -Deoxy-D-Glucose (2-DG), a drug used for the treatment of COVID-19 patients, has called for Expression of Interest (EoI) to transfer the technology to Indian pharmaceutical industries for production.

New-delhi , Delhi , India , Shalini-bhardwaj , Technical-assessment-committee , Technology-to , Institute-of-nuclear-medicine , Development-organisation , Defence-research , Nuclear-medicine , Allied-sciences , Indian-pharmaceutical

2DG approved for emergency use as adjunct therapy for COVID-19 patients: DRDO

New Delhi [India], June 1 (ANI): The Defence Research and Development Organisation's (DRDO) on Tuesday said that the anti-COVID drug 2DG is approved for emergency use as an adjunct therapy to the standard of care in the treatment of coronavirus patients in hospital settings.

Hyderabad , Andhra-pradesh , India , New-delhi , Delhi , Rajnath-singh , Union-health-ministry , Centre-for-cellular , Institute-of-nuclear-medicine , Development-organisation , Defence-research , Defence-minister-rajnath-singh

Over 10,000 doses of DRDO's anti-COVID-19 drug 2-DG to be available from next week

Source:
Highlights
The first batch of 10,000 doses of the 2-DG drug would be launched early next week, informed DRDO on May 14.
The 2-DG drug helps in faster recovery of the hospitalised COVID-19 patients and reduces oxygen dependence.
New Delhi: The first batch of 10,000 doses of the 2-DG drug for treating COVID-19 patients would be launched early next week, informed Defence Research and Development Organisation officials on Friday (May 14, 2021).
The official informed, "The first batch of 10,000 doses of 2-DG medicine for the treatment of COVID-19 infected patients would be launched early next week and will be given to patients."
"The drug manufacturers are working on ramping up the production of the medicine for future use. The drug has been developed by a team of DRDO scientists including Dr Anant Narayan Bhatt", informed DRDO officials.

Karnataka , India , Hyderabad , Andhra-pradesh , New-delhi , Delhi , Anant-narayan-bhatt , Karnataka-health , Institute-of-nuclear-medicine , Development-organisation , Defence-research , Karnataka-health-ministerk-sudhakar

2-deoxy-D-glucose: DRDO's anti-COVID-19 drug is safe, will help patients recover faster, says INMAS scientist

Source:
ANI
New Delhi: Dr Sudhir Chandna, Institute of Nuclear Medicine and Allied Sciences (INMAS) scientist has said the recently approved anti-COVID-19 drug 2-deoxy-D-glucose (2-DG) is completely safe and will help patients recover faster.
"During clinical trials, it has yielded an effective result in curing patients infected with COVID-19. The medicine has gone through clinical trials on around 110 patients in the second phase. In the third phase, it was tried on 220 patients. It has shown better efficacy in phase two itself as compared to the standard care," Dr Chandna said.
"Recovery was two to three days faster for COVID-19 patients," he added.

Hyderabad , Andhra-pradesh , India , New-delhi , Delhi , Sudhir-chandna , Institute-of-nuclear-medicine , Development-organisation , Defence-research , Nuclear-medicine , Allied-sciences , 2-deoxyd-glucose